SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Jack London

PatientJack London
Date of birth1987-01-12
IdentifiersMRN HR-ET010-SYN; SSN (made up) 000-10-4482
Document date2026-10-27
AuthorEleanor Whitcombe-Ibe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twelve-week review. [S]

History of Present Illness

Mr. London has had no alcohol for eight weeks. He has taken dapagliflozin for two weeks with a little more passing of urine and no dizziness, genital symptoms or illness, and has not needed the sick-day rules. He takes losartan 100 mg, naltrexone, thiamine and vitamin D3 every morning. His home readings average 120/76. He writes every morning and has started a new novel; he swims or rides in the late morning. He would like to stop smoking in the new year. He asks what the next months hold for his kidneys. [S]

ElementDetail
AlcoholNone for eight weeks; PEth 6 ng/mL; AUDIT 9 for the past three months
KidneysCreatinine 2.13 mg/dL, eGFR 40 after two weeks of dapagliflozin; potassium 4.7; urine albumin 96 mg/g
Liver testsAST 29, ALT 26, GGT 54 U/L; MCV 96 fL
MoodPHQ-9 4, item 9 scored 0; GAD-7 4

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight down 3.3 kg since intake
GenitourinaryPositivePassing a little more urine; no burning, itching or discharge
CardiovascularNegativeNo dizziness on standing; no ankle swelling
PsychiatricNegativeMood good; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intakeOne tablet by mouth twice a day, self-directedOral route2024-08-01 to 2026-08-04stoppedS
Losartan 50 mg oral tablet once dailyOne tablet by mouth every morningOral route2026-08-04 to 2026-09-15completedS
Losartan 100 mg oral tablet once dailyOne tablet by mouth every morningOral route2026-09-15activeS
Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone checkUp to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or drivingOral route2026-08-04 to 2026-08-08completedS
Thiamine 100 mg oral tablet once dailyOne tablet by mouth dailyOral route2026-08-04activeS
Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxenOne to two tablets by mouth every six hours as needed; no more than four tablets a dayOral route2026-08-04activeS
Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicinesOne tablet by mouth every morningOral route2026-08-18activeS
Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once dailyOne tablet by mouth dailyOral route2026-09-15activeS
Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgeryOne tablet by mouth every morning; sick-day rules in writingOral route2026-10-13activeS
Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicineApply 4 g to the ankle four times a day for up to seven daysTopical route2026-09-01 to 2026-09-08completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-27Body height173cmS
2026-10-27Body weight80.9kgS
2026-10-27Body mass index (BMI) [Ratio]27kg/m2S
2026-10-27Systolic blood pressure122mm[Hg]S
2026-10-27Diastolic blood pressure78mm[Hg]S
2026-10-27Heart rate70/minS
2026-10-27Respiratory rate14/minS
2026-10-27Body temperature36.6CelS
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-27Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-27Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-10-27Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-10-27Urea nitrogen [Mass/volume] in Serum or Plasma24mg/dL7-20 mg/dLHighS
2026-10-27Creatinine [Mass/volume] in Serum or Plasma2.13mg/dL0.74-1.35 mg/dLHighS
2026-10-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M40mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
2026-10-27Albumin/Creatinine [Mass Ratio] in Urine96mg/gBelow 30 mg/g A1; 30 to 300 A2; above 300 A3HighS
2026-10-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L10-40 U/LNormalS
2026-10-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L9-46 U/LNormalS
2026-10-27Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma54U/L8-61 U/LNormalS
2026-10-27MCV [Entitic mean volume] in Red Blood Cells by Automated count96fL80-100 fLNormalS
2026-10-27Phosphatidylethanol [Mass/volume] in Blood6ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingNormalS
2026-10-27Total score [AUDIT]9{score}S
2026-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-10-27Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]4{score}S

Physical Exam

Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/78, pulse 70; weight 80.9 kg, BMI 27.0
CardiovascularRegular rhythm; no edema; no fall in blood pressure on standing
AbdomenSoft; liver edge not felt

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultationresolvedconfirmed R94.4S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease.
Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney diseaseactiveconfirmed N18.32S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys.
Hypertensive chronic kidney disease, untreated until intakeactiveconfirmed I12.9S — Synthetic modern diagnosis made at the consultation.
Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mLactiveconfirmed F10.20S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking.
Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intakeactiveconfirmed K70.0S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver.
Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its placeresolvedconfirmed Z79.1S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis.
Cigarette smoking, about ten a day; not ready to stop while he stops drinkingactiveconfirmed F17.210S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim.
Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeksresolvedconfirmed S93.401AS — Synthetic acute injury; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationStandardized office blood pressure (five minutes' rest, validated device, average of readings)Every visitCompleted today122/78 mmHg; home average 120/76
LaboratoryPotassium and creatinine after starting or changing losartan or an SGLT2 inhibitorTwo to four weeks after each start or changeCompleted todayTwo weeks after dapagliflozin: potassium 4.7 mmol/L; creatinine 2.13 mg/dL, an expected 9 percent fall in eGFR
LaboratoryCreatinine with eGFR and urine albumin-to-creatinine ratioG3b A2: twice a year, and at each medicine checkCompleted todayeGFR 40; urine albumin 96 mg/g
LaboratoryElectrolytes and bicarbonateWith each kidney testCompleted todaySodium 139; bicarbonate 23; urea nitrogen 24 mg/dL
LaboratoryCalcium, phosphate and PTHG3a to G3b: every six to twelve monthsUp to dateDue in six months
Medication safetySGLT2 inhibitor safety: sick-day rules, ketoacidosis, genital infection, volumeEvery visitCompleted todayNo genital infection, dizziness or illness; sick-day rules understood
Medication safetyMedication reconciliation: no NSAIDs, kidney dosing, contrast safetyEvery visitCompleted todayNo NSAIDs; all doses checked for his eGFR
Self-managementLifestyle: sodium below 2 g a day, activity, diet, weightEvery visitCompleted todayLess salt; swims or rides most days; 3.3 kg lost
Self-managementVaccination review (pneumococcal, influenza, hepatitis B, COVID-19)YearlyCompleted todaySecond hepatitis B dose today; influenza, PCV20 and hepatitis A given at the preventive visit
SurveyDrinking since the last visit (self-report)Every visitCompleted todayNone for eight weeks
LaboratoryPEthAt baseline and every four to six weeks in early recoveryCompleted today6 ng/mL: abstinence
SurveyAUDITAt intake and at three monthsCompleted today9 for the past three months, from 27
LaboratoryLiver tests (AST, ALT, GGT) on naltrexoneAt baseline, at four to six weeks, then every few monthsCompleted todayAST 29, ALT 26, GGT 54 U/L; MCV 96 fL
Medication safetyNaltrexone safety: opioid use, nausea, wallet cardEvery visitCompleted todayNo nausea; no opioid
ReferralAddiction-focused counseling and mutual helpWeekly in early recovery, then every two weeksCompleted todayTen sessions; every two weeks from now
SurveyPHQ-9 and GAD-7At intake and at follow-upCompleted todayPHQ-9 4 with item 9 scored 0; GAD-7 4
SurveySuicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; firearms locked; 988 card carried
Self-managementTobacco use and readiness to stopEvery visitCompleted todayReady to set a quit date

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), second of two doses [S]

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)

Follow-up: Nephrology review in three weeks. Primary care in three months with creatinine, eGFR, urine albumin, potassium and PEth. Counseling every two weeks. The clinic or 988 at any hour. [S]